Here is what I found. Phase II studies have been performed in India by APAC Biotech. This addressed the use for refractory cancer specifically colo-rectal, ovarian, non-small cell lung and prostate. It is Autologous Dendritic Cell Immunotherapy. This appears to be similar to Provenge, but I haven't found how it actually compares. It is a cell replacement therapy dealing with the dendritic cells as is Provenge by Dendreon. This appears to be some time before any FDA assessment as it would need to at least get through Phase III trials.
Regarding Provenge, we have seen several men use it on the forum. Most notably Todd1963 who was an early user and swears that it has helped him greatly. Generally it is indicated and on label use for asymptomatic mCRPC (metastatic castrate resistant prostate cancer). However, it can be and is used off label in other PCa settings, just a matter of reimbursement issues. There are several studies to determine its effectiveness earlier in the treatment sequence (PROTECT), comparing use with other forms of ADT (NeoACT) and where in the treatment sequence it might be best (STAND).
You should discuss this with your father's doctors and could also reach out to other PCa medical oncologists known for their specialized treatment of advanced disease like Oliver Sartor at Tulane, Eugene Kwan at Mayo Clinic and MD Anderson. In my urologist's practice, they have been strong users of Provenge and keep a database of their high risk and advanced stage men to help them determine the best time to introduce it in the treatment sequence. The last time I spoke with my urologist about
it he said they normally include Provenge in treatments a few hundred times each year.
Here is a link to information you may find useful. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131740/
The authors are at Duke University Medical Center, which is generally well regarded for their PCa work. It appears they are also regular users of Provenge in their clinical practice and could be people you could contact for information and assessment.
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard and Jalyn started on 10-7-2010. IMRT to prostate and lymph nodes started on 11-8-2010, HDR Brachytherapy December 6 and 13, 2010.
PSA < .1 since February 2011. Located in Cumming Georgia north of Atlanta
Post Edited (JNF) : 8/9/2019 8:47:03 AM (GMT-6)